MX2014014902A - Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. - Google Patents

Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.

Info

Publication number
MX2014014902A
MX2014014902A MX2014014902A MX2014014902A MX2014014902A MX 2014014902 A MX2014014902 A MX 2014014902A MX 2014014902 A MX2014014902 A MX 2014014902A MX 2014014902 A MX2014014902 A MX 2014014902A MX 2014014902 A MX2014014902 A MX 2014014902A
Authority
MX
Mexico
Prior art keywords
apomorphine
compositions
organic acids
neurological
parkinson
Prior art date
Application number
MX2014014902A
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Mara Nemas
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of MX2014014902A publication Critical patent/MX2014014902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención presente proporciona composiciones farmacéuticas estables líquidas o semisólidas de apomorfina, más particularmente una composición que comprende apomorfina y un ácido orgánico, que es útil en el tratamiento de enfermedades o trastornos neurológicos o de movimiento, por ejemplo, la enfermedad de Parkinson, o las condiciones asociadas con el mismo.
MX2014014902A 2012-06-05 2013-06-05 Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. MX2014014902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655633P 2012-06-05 2012-06-05
PCT/IL2013/050487 WO2013183055A1 (en) 2012-06-05 2013-06-05 Compositions comprising apomorphine and organic acids and uses thereof

Publications (1)

Publication Number Publication Date
MX2014014902A true MX2014014902A (es) 2015-03-04

Family

ID=48790516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014902A MX2014014902A (es) 2012-06-05 2013-06-05 Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.

Country Status (18)

Country Link
US (3) US9999674B2 (es)
EP (2) EP3456315A1 (es)
JP (2) JP6257604B2 (es)
CN (2) CN104349768B (es)
AU (1) AU2013273138B2 (es)
BR (1) BR112014030265A2 (es)
CA (1) CA2875446A1 (es)
DK (1) DK2854764T3 (es)
ES (1) ES2715028T3 (es)
HU (1) HUE042425T2 (es)
MX (1) MX2014014902A (es)
NZ (1) NZ703341A (es)
PL (1) PL2854764T3 (es)
PT (1) PT2854764T (es)
RU (1) RU2688672C2 (es)
TR (1) TR201903492T4 (es)
WO (1) WO2013183055A1 (es)
ZA (1) ZA201409516B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
CN107548388A (zh) * 2014-12-23 2018-01-05 纽罗德姆有限公司 阿朴吗啡的晶体形态及其用途
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
AU2016333486B2 (en) * 2015-09-28 2022-02-03 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
WO2019009355A1 (ja) * 2017-07-06 2019-01-10 山田　健一 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法
RU2020126518A (ru) * 2018-01-18 2022-02-21 ЛЕУКОС БИОТЕК, Эс Эль Кристаллическая форма твердых частиц сокристалла апоморфин-пальмитиновая кислота
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer
CN116456998A (zh) * 2020-10-29 2023-07-18 睁开眼治疗股份有限公司 咖啡因组合物
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine
KR20240069750A (ko) * 2021-09-12 2024-05-20 지엠피 바이오테크놀로지 리미티드 신경 장애의 치료
US20230255956A1 (en) * 2022-02-01 2023-08-17 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing nalbuphine
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU72463A2 (ru) 1947-07-03 1947-11-30 М.П. Опарина Способ получени апоморфина
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
SU555887A1 (ru) 1974-01-07 1977-04-30 Стабилизатор водного раствора апоморфина гидрохлорида
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0252290B1 (en) 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5284512A (en) 1991-03-06 1994-02-08 Donlar Corporation Polyaspartic acid and its salts for dispersing suspended solids
UA41502C2 (uk) 1991-12-20 2001-09-17 Ново Нордіск А/С Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2133737A1 (en) 1992-04-07 1993-10-14 James E. Seely Lyophilized somatotropin formulations
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
EP1077692B1 (en) 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
IT1303684B1 (it) 1998-10-30 2001-02-23 Chiesi Farma Spa Formulazioni di apomorfina in soluzione stabili nel tempo.
JP4959864B2 (ja) 1998-11-11 2012-06-27 大日本住友製薬株式会社 グルタミン酸塩含有液剤
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20020086876A1 (en) * 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20050233945A1 (en) 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
CN1720054A (zh) 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
EP1496868A1 (en) 2002-04-11 2005-01-19 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
JP2007509971A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン メトホルミンの増加された吸収のための組成物及び投与形態物
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EP1789052A4 (en) * 2004-09-07 2008-05-21 Univ Laval COMPOSITION AND METHOD FOR INTRODUCING OR RESTORING THE MOTION FUNCTIONS IN A MAMMALIAN
HUE028833T2 (en) 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
US20060241183A1 (en) 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
US20070148238A1 (en) 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
EP2010184B1 (en) 2006-04-06 2013-01-09 Nupathe Inc. Implants for the treatment of dopamine associated states
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UA95954C2 (ru) 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
KR101520311B1 (ko) * 2007-05-21 2015-05-14 도레이 카부시키가이샤 특정 유기산을 함유하는 경구 제제, 및 경구 제제의 용출성과 화학적 안정성의 개선 방법
RU2370261C2 (ru) * 2007-08-03 2009-10-20 Закрытое Акционерное Общество "Биокад" Стабильная эмульсия для парентерального введения плохо растворимых в воде соединений, обладающих противоопухолевой активностью, и способ ее получения
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20110150946A1 (en) * 2008-08-22 2011-06-23 Al-Ghananeem Abeer M Transdermal Delivery of Apomorphine Using Microneedles
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
MX364974B (es) 2009-05-19 2019-05-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
PL2640370T3 (pl) 2010-11-15 2018-09-28 Neuroderm Ltd Kompozycje do dostarczania przezskórnego substancji czynnych
ES2776734T3 (es) 2010-11-15 2020-07-31 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
US20180140610A1 (en) 2014-09-18 2018-05-24 Neuroderm, Ltd. Opipramol patch
CN107548388A (zh) 2014-12-23 2018-01-05 纽罗德姆有限公司 阿朴吗啡的晶体形态及其用途

Also Published As

Publication number Publication date
JP6257604B2 (ja) 2018-01-10
JP2018070633A (ja) 2018-05-10
JP2015518880A (ja) 2015-07-06
RU2688672C2 (ru) 2019-05-22
ES2715028T3 (es) 2019-05-31
RU2014152208A (ru) 2016-07-27
CN104349768B (zh) 2017-11-07
JP6458124B2 (ja) 2019-01-23
NZ703341A (en) 2016-11-25
EP2854764A1 (en) 2015-04-08
CN107693486A (zh) 2018-02-16
DK2854764T3 (en) 2019-04-08
ZA201409516B (en) 2016-03-30
PT2854764T (pt) 2019-03-21
US9999674B2 (en) 2018-06-19
EP2854764B1 (en) 2018-12-12
HUE042425T2 (hu) 2019-06-28
EP3456315A1 (en) 2019-03-20
PL2854764T3 (pl) 2019-07-31
AU2013273138B2 (en) 2017-06-15
TR201903492T4 (tr) 2019-04-22
AU2013273138A1 (en) 2015-01-22
CN104349768A (zh) 2015-02-11
WO2013183055A1 (en) 2013-12-12
US20160067339A1 (en) 2016-03-10
US9381249B2 (en) 2016-07-05
US10525134B2 (en) 2020-01-07
US20150182523A1 (en) 2015-07-02
CA2875446A1 (en) 2013-12-12
US20180303939A1 (en) 2018-10-25
BR112014030265A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EP4219713A3 (en) Products and compositions
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
CA2871471C (en) Dna-pk inhibitors
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
CL2012001073A1 (es) Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias.
GB2511685A (en) Muscarinic m1 receptor agonists
MY162502A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
NZ702239A (en) Heteroaryl compounds and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration